Advertisement

Dupixent, Juvéderm Vollure XC, Bavencio Approvals
Dupixent, Juvéderm Vollure XC, Bavencio Approvals

Dupixent, Juvéderm Vollure XC, Bavencio Approvals

The FDA has approved Regeneron's injectable Dupixent (dupilumab) to treat adults with moderate-to-severe eczema. It will be marketed by Regeneron and Sanofi Genzyme in the US. Allergan's Juvéderm Vollure XC has received FDA approval based on a pivotal clinical trial in which 59 percent of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. EMD Serono's Bavencio (avelumab) has received FDA fast-track approval for treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma. And research shows no significant difference in outcomes when topical or oral antibiotics are added to standard eczema treatment with steroid creams and emollients.

Advertisement